新型コロナウイルスワクチン副反応調査の報告

Matsumoto, Naomi; Higuchi, Chigusa; Mitsuhashi, Toshiharu; Hagiya, Hideharu; Takao, Soshi; Yorifuji, Takashi

doi:10.4044/joma.134.35

Cited by 3 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence proportions of local and systemic reactions did not show a clear increase with the number of doses administered. Adverse reactions were less frequent in this population compared with adult populations, 27,28 and no individuals experienced fever above 39°C. The incidence of post‐vaccination adverse reactions, as reported in Pfizer's submission to the FDA, was low and not statistically different from the placebo group 18 .…”

Section: Discussionmentioning

confidence: 59%

“…T A B L E 4 Association of previous infection/influenza vaccine co-administration with post-vaccination fever. adult populations, 27,28 and no individuals experienced fever above 39°C. The incidence of post-vaccination adverse reactions, as reported in Pfizer's submission to the FDA, was low and not statistically different from the placebo group.…”

Section: Respondents No (%)mentioning

confidence: 93%

See 1 more Smart Citation

Adverse reactions in young children receiving the coronavirus disease 2019 vaccine

Matsumoto,

Shimizu,

Yokoyama

et al. 2023

Pediatrics International

View full text Add to dashboard Cite

BackgroundWe sought to investigate the occurrence of adverse reactions in Japanese children aged 6 months to 4 years who received the BNT162b2 coronavirus disease 2019 (COVID‐19) vaccine, to examine parental considerations, and to evaluate potential risk factors associated with post‐vaccination fever.MethodsThis cross‐sectional survey study targeted 1617 children aged 6 months to 4 years who received their primary doses of BNT162b2 from November 10, 2022, to April 30, 2023, in Okayama Prefecture. We surveyed the occurrence of local and systemic reactions within 1 week after vaccination, and described the incidence proportions of adverse reactions for 515 participants overall and by age group. The study also examined the impact of previous COVID‐19 infection and co‐administration of the seasonal influenza vaccine on post‐vaccination fever. A survey also assessed parents' reasons for vaccinating their children and the sources of information they used.ResultsAdverse reactions were infrequent (5.2%, with fever ≥37.5°C; no cases exceeded 39°C) and did not increase with vaccine doses administered. The risk of post‐vaccination fever was not statistically associated with a history of COVID‐19—the adjusted risk ratio (aRR) was 0.99, and the 95% confidence interval (CI) was 0.41–2.39—but was associated with co‐administration of the seasonal influenza vaccine (aRR 3.24, 95% CI 1.14–9.18). Parental decisions regarding vaccination were influenced by official government guidelines and primary care physicians' opinion.ConclusionThis study provides valuable insight into the safety profile of the BNT162b2 vaccine in Japanese children aged 6 months to 4 years. Further research involving larger cohorts and appropriate control groups is needed.

show abstract

Section: Discussionmentioning

confidence: 59%

Section: Respondents No (%)mentioning

confidence: 93%

Adverse reactions in young children receiving the coronavirus disease 2019 vaccine

Matsumoto,

Shimizu,

Yokoyama

et al. 2023

Pediatrics International

View full text Add to dashboard Cite

show abstract

“…The frequency of systemic adverse reactions in children was significantly lower than that in 8,599 healthcare workers in Okayama Prefecture, comparable to the adult official survey in Japan. [5] The frequency of fever after the second dose was as low as 11.6% in children, approximately 1/3 of that of adults (37.5%). Similarly, the reaction frequencies of fatigue (children 22.0% versus adults 69.7%) and headache (children 14.8% versus adults 51.1%) were lower in children than in adults.…”

Section: Addressmentioning

confidence: 93%

Adverse Reactions and Attitudes Toward the BNT162b2 COVID-19 Vaccine in Children 5 to 11 Years of Age in Japan

Matsumoto

Shimizu

Yokoyama

et al. 2023

Journal of Epidemiology

Self Cite

View full text Add to dashboard Cite

show abstract

“… 1 , 2 Especially mRNA-1273, one of the vaccines primarily used in Japan, tends to be eschewed because of its relatively high reported incidence of adverse reactions. 3 Despite an outstanding clinical question, few studies have investigated whether an association exists between fever, a typical adverse reaction, and increased antibody titers after vaccination with mRNA-1273, 4 and none have examined the association after the third dose.…”

mentioning

confidence: 99%

Association Between Fever and Antibody Titer Trends After a Third Dose of the mRNA-1273 Vaccine

Matsumoto

Kadowaki

Matsuo

et al. 2022

Journal of Epidemiology

Self Cite

View full text Add to dashboard Cite

show abstract

新型コロナウイルスワクチン副反応調査の報告

Cited by 3 publications

References 8 publications

Adverse reactions in young children receiving the coronavirus disease 2019 vaccine

Adverse reactions in young children receiving the coronavirus disease 2019 vaccine

Adverse Reactions and Attitudes Toward the BNT162b2 COVID-19 Vaccine in Children 5 to 11 Years of Age in Japan

Association Between Fever and Antibody Titer Trends After a Third Dose of the mRNA-1273 Vaccine

Contact Info

Product

Resources

About